Artiva Total Stockholder Equity vs Long Term Debt Analysis

ARTV Stock

11.04 0.64 6.15%

Artiva Biotherapeutics, financial indicator trend analysis is way more than just evaluating Artiva Biotherapeutics, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Artiva Biotherapeutics, is a good investment. Please check the relationship between Artiva Biotherapeutics, Total Stockholder Equity and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artiva Biotherapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Total Stockholder Equity vs Long Term Debt

Total Stockholder Equity vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Artiva Biotherapeutics, Total Stockholder Equity account and Long Term Debt. At this time, the significance of the direction appears to have strong relationship.

The correlation between Artiva Biotherapeutics,'s Total Stockholder Equity and Long Term Debt is 0.77. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Artiva Biotherapeutics, Common, assuming nothing else is changed. The correlation between historical values of Artiva Biotherapeutics,'s Total Stockholder Equity and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Artiva Biotherapeutics, Common are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Stockholder Equity i.e., Artiva Biotherapeutics,'s Total Stockholder Equity and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Long Term Debt

Long-term debt is a debt that Artiva Biotherapeutics, has held for over one year. Long-term debt appears on Artiva Biotherapeutics, Common balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Artiva Biotherapeutics, Common balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Artiva Biotherapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Artiva Biotherapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artiva Biotherapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Selling General Administrative is likely to climb to about 14.3 M in 2024, whereas Tax Provision is likely to drop slightly above 68.8 K in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	248K	1.2M	2.3M	2.4M
Total Operating Expenses	55.3M	64.8M	64.2M	55.7M

Reconciled Depreciation Total Operating Expenses

Artiva Biotherapeutics, fundamental ratios Correlations

	Net Debt	Long Term Debt	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Non Current Liabilities Other	Net Working Capital	Short Term Debt
Net Debt		0.15	-0.92	-0.38	-0.87	-0.83	0.6	-0.43	0.6	0.62	-0.96	-0.51	-0.85	-0.95	0.15	-0.8	-0.38	-0.6	-0.5	-0.81	0.6	-0.43	-0.95	0.7	-0.95	-0.37
Long Term Debt	0.15		-0.46	-0.53	-0.49	-0.38	0.77	-0.54	0.74	0.69	-0.32	-0.56	-0.02	-0.4	0.83	-0.57	-0.53	-0.46	-0.64	-0.56	0.77	-0.56	-0.41	0.73	-0.41	-0.57
Total Assets	-0.92	-0.46		0.64	0.99	0.93	-0.85	0.68	-0.84	-0.85	0.96	0.74	0.69	0.99	-0.44	0.96	0.64	0.79	0.74	0.96	-0.85	0.68	0.99	-0.87	0.98	0.64
Short Long Term Debt Total	-0.38	-0.53	0.64		0.74	0.75	-0.88	1.0	-0.9	-0.89	0.44	0.99	-0.11	0.52	-0.66	0.81	1.0	0.93	0.92	0.81	-0.88	1.0	0.52	-0.61	0.47	0.99
Other Current Liab	-0.87	-0.49	0.99	0.74		0.96	-0.9	0.78	-0.9	-0.9	0.92	0.83	0.57	0.96	-0.49	0.98	0.74	0.87	0.81	0.99	-0.9	0.78	0.96	-0.85	0.94	0.74
Total Current Liabilities	-0.83	-0.38	0.93	0.75	0.96		-0.83	0.78	-0.83	-0.8	0.89	0.82	0.49	0.9	-0.31	0.91	0.75	0.93	0.72	0.92	-0.83	0.76	0.9	-0.69	0.86	0.72
Total Stockholder Equity	0.6	0.77	-0.85	-0.88	-0.9	-0.83		-0.91	1.0	0.98	-0.69	-0.93	-0.24	-0.77	0.77	-0.95	-0.88	-0.88	-0.94	-0.94	1.0	-0.91	-0.78	0.89	-0.75	-0.9
Property Plant And Equipment Net	-0.43	-0.54	0.68	1.0	0.78	0.78	-0.91		-0.92	-0.91	0.49	1.0	-0.05	0.57	-0.67	0.85	1.0	0.94	0.94	0.85	-0.91	1.0	0.58	-0.66	0.53	0.99
Retained Earnings	0.6	0.74	-0.84	-0.9	-0.9	-0.83	1.0	-0.92		0.99	-0.68	-0.94	-0.23	-0.76	0.78	-0.95	-0.9	-0.88	-0.96	-0.95	1.0	-0.93	-0.77	0.89	-0.75	-0.91
Accounts Payable	0.62	0.69	-0.85	-0.89	-0.9	-0.8	0.98	-0.91	0.99		-0.68	-0.94	-0.26	-0.77	0.8	-0.96	-0.89	-0.85	-0.98	-0.96	0.98	-0.93	-0.78	0.91	-0.76	-0.91
Cash	-0.96	-0.32	0.96	0.44	0.92	0.89	-0.69	0.49	-0.68	-0.68		0.56	0.82	0.99	-0.22	0.85	0.44	0.67	0.54	0.86	-0.69	0.48	0.99	-0.76	0.98	0.42
Non Current Assets Total	-0.51	-0.56	0.74	0.99	0.83	0.82	-0.93	1.0	-0.94	-0.94	0.56		0.04	0.64	-0.67	0.89	0.99	0.95	0.95	0.89	-0.93	1.0	0.65	-0.71	0.6	0.99
Non Currrent Assets Other	-0.85	-0.02	0.69	-0.11	0.57	0.49	-0.24	-0.05	-0.23	-0.26	0.82	0.04		0.79	0.06	0.48	-0.11	0.14	0.11	0.49	-0.24	-0.04	0.78	-0.54	0.81	-0.1
Cash And Short Term Investments	-0.95	-0.4	0.99	0.52	0.96	0.9	-0.77	0.57	-0.76	-0.77	0.99	0.64	0.79		-0.36	0.91	0.52	0.71	0.64	0.91	-0.77	0.57	1.0	-0.84	1.0	0.52
Common Stock Shares Outstanding	0.15	0.83	-0.44	-0.66	-0.49	-0.31	0.77	-0.67	0.78	0.8	-0.22	-0.67	0.06	-0.36		-0.63	-0.66	-0.45	-0.84	-0.61	0.77	-0.7	-0.36	0.79	-0.37	-0.72
Non Current Liabilities Total	-0.8	-0.57	0.96	0.81	0.98	0.91	-0.95	0.85	-0.95	-0.96	0.85	0.89	0.48	0.91	-0.63		0.81	0.87	0.9	1.0	-0.95	0.85	0.91	-0.91	0.9	0.82
Capital Lease Obligations	-0.38	-0.53	0.64	1.0	0.74	0.75	-0.88	1.0	-0.9	-0.89	0.44	0.99	-0.11	0.52	-0.66	0.81		0.93	0.92	0.81	-0.88	1.0	0.52	-0.61	0.47	0.99
Other Current Assets	-0.6	-0.46	0.79	0.93	0.87	0.93	-0.88	0.94	-0.88	-0.85	0.67	0.95	0.14	0.71	-0.45	0.87	0.93		0.82	0.88	-0.88	0.92	0.71	-0.61	0.66	0.9
Other Stockholder Equity	-0.5	-0.64	0.74	0.92	0.81	0.72	-0.94	0.94	-0.96	-0.98	0.54	0.95	0.11	0.64	-0.84	0.9	0.92	0.82		0.89	-0.94	0.96	0.65	-0.83	0.63	0.95
Total Liab	-0.81	-0.56	0.96	0.81	0.99	0.92	-0.94	0.85	-0.95	-0.96	0.86	0.89	0.49	0.91	-0.61	1.0	0.81	0.88	0.89		-0.94	0.85	0.92	-0.9	0.9	0.82
Net Invested Capital	0.6	0.77	-0.85	-0.88	-0.9	-0.83	1.0	-0.91	1.0	0.98	-0.69	-0.93	-0.24	-0.77	0.77	-0.95	-0.88	-0.88	-0.94	-0.94		-0.91	-0.78	0.89	-0.75	-0.9
Property Plant And Equipment Gross	-0.43	-0.56	0.68	1.0	0.78	0.76	-0.91	1.0	-0.93	-0.93	0.48	1.0	-0.04	0.57	-0.7	0.85	1.0	0.92	0.96	0.85	-0.91		0.58	-0.68	0.53	1.0
Total Current Assets	-0.95	-0.41	0.99	0.52	0.96	0.9	-0.78	0.58	-0.77	-0.78	0.99	0.65	0.78	1.0	-0.36	0.91	0.52	0.71	0.65	0.92	-0.78	0.58		-0.85	1.0	0.52
Non Current Liabilities Other	0.7	0.73	-0.87	-0.61	-0.85	-0.69	0.89	-0.66	0.89	0.91	-0.76	-0.71	-0.54	-0.84	0.79	-0.91	-0.61	-0.61	-0.83	-0.9	0.89	-0.68	-0.85		-0.86	-0.65
Net Working Capital	-0.95	-0.41	0.98	0.47	0.94	0.86	-0.75	0.53	-0.75	-0.76	0.98	0.6	0.81	1.0	-0.37	0.9	0.47	0.66	0.63	0.9	-0.75	0.53	1.0	-0.86		0.48
Short Term Debt	-0.37	-0.57	0.64	0.99	0.74	0.72	-0.9	0.99	-0.91	-0.91	0.42	0.99	-0.1	0.52	-0.72	0.82	0.99	0.9	0.95	0.82	-0.9	1.0	0.52	-0.65	0.48

Click cells to compare fundamentals

Artiva Biotherapeutics, Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Artiva Stock Analysis

When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Artiva Total Stockholder Equity vs Long Term Debt Analysis

Total Stockholder Equity vs Long Term Debt

Total Stockholder Equity vs Long Term Debt Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Long Term Debt

Artiva Biotherapeutics, fundamental ratios Correlations

Artiva Biotherapeutics, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Artiva Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total
Retained Earnings	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net

Other Stockholder Equity	- 0.98	Accounts Payable
Total Liab	- 0.96	Accounts Payable
Non Current Liabilities Total	- 0.96	Accounts Payable
Other Stockholder Equity	- 0.96	Retained Earnings
Cash	- 0.96	Net Debt
Net Invested Capital	- 0.95	Non Current Liabilities Total